D-gluconic acid hydrazide | 69489-87-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-gluconic acid hydrazide
• 英文别名: gluconic acid hydrazide；D-gluconohydrazide；Gluconoylhydrazine；D-gluconic acid hydrazide；D-gluco-2,3,4,5,6-Pentahydroxy-hexansaeure-hydrazid；D-Gluconsaeure-hydrazid；(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanehydrazide
• CAS: 69489-87-8；130538-62-4；147598-40-1；3868-12-0
• 化学式: C₆H₁₄N₂O₆
• 分子量: 210.187
• InChiKey: DSSOAANULUSBGQ-SQOUGZDYSA-N

物化性质

• 沸点：
  738.6±60.0 °C(predicted)
• 密度：
  1.665±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  156
• 氢给体数：
  7
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  D-gluconic acid hydrazide 、 柔红霉素 盐酸盐 以 甲醇 为溶剂， 以47%的产率得到(2R,3S,4R,5R)-2,3,4,5,6-Pentahydroxy-hexanoic acid [1-[(2S,4S)-4-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-2-yl]-eth-(E)-ylidene]-hydrazide; hydrochloride
  参考文献：
  名称：

  Synthesis and properties of hydrazones of the antitumor antibiotic rubomycin

  摘要：

  DOI：

  10.1007/bf00758626
• 作为产物：
  描述：

  葡糖酸 在 盐酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 0.03h， 生成 D-gluconic acid hydrazide
  参考文献：
  名称：

  MAOS ofD‐Gluconic Acid,D‐Glucono‐1,4‐ and 1,5‐Lactones, Esters, Hydrazides, and Benzimidazoles Thereof

  摘要：

  Microwave-assisted organic synthesis (MAOS) of D-gluconic acid can be efficiently done by oxidation of D- glucose with bromine water, upon irradiation with microwave ( MW). It was also used for the conversion of D-gluconic acid to ethyl D-gluconate, D-glucono-1,4- and 1,5-lactones, gluconyl hydrazide, and gluconyl phenylhydrazide in yields comparable to those obtained by conventional methods, but in much shorter times. A convenient microwave- mediated condensation of D- gluconic acid with o-phenylenediamines provided the respective acyclonucleoside benzimidazole in short time and good yield.[GRAPHICS]

  DOI：

  10.1080/07328300701540258

文献信息

• Synthesis and antimicrobial evaluation of some annelated phthalazine derivatives and acyclo C-nucleosides from 1-chloro-4-(2,4,6-trimethylphenyl) phthalazine precursor
  作者：Maher Abdel Aziz El-Hashash、Ahmed Youssef Soliman、Ibrahim Essam ELSHAMY

  DOI：10.3906/kim-1111-52

  日期：——

  A highly efficient and versatile synthetic approach to the synthesis of annelated phthalazine derivatives viz. 1,2,4-triazolo [3,4-a]phthalazine 11a,b, 14, 18, 19a,b, 29-31, 33, 1,2,4-triazino [3,4-a]phthalazine 25a,b-28, 1,3,5-triazino[4,3-a]phthalazine 22, tetrazolo[5,1-a] phthalazine 23, imidazophthalazine 9a,b,15, and pyrimidinophthlazine 6, 10, 16, 17, 20 is presented. Moreover, acyclo C-nucleoside and double headed acyclo C-nucleoside of 1,2,4-triazolo[3,4-a]phthalazine 12, 13 were obtained via heterocyclization reaction of 1-chloro-4-(2,4,6-trimethylphenyl) phthalazine (4) with gluconic acid hydrazide and galactaric acid bis hydrazide, respectively. The new compounds were synthesized with the objective of studying their antimicrobial activity.

  本文介绍了一种高效且通用的合成方法，用于制备多环并联吡嗪衍生物，包括1,2,4-三唑并[3,4-a]吡嗪11a,b，14，18，19a,b，29-31，33，1,2,4-三嗪并[3,4-a]吡嗪25a,b-28，1,3,5-三嗪并[4,3-a]吡嗪22，四唑并[5,1-a]吡嗪23，咪唑吡嗪9a,b，15，以及嘧啶吡嗪6，10，16，17，20。此外，通过1-氯-4-(2,4,6-三甲基苯基)吡嗪（4）与葡萄糖酸酰肼和半乳糖二酸双酰肼的杂环化反应，分别合成了1,2,4-三唑并[3,4-a]吡嗪的无环C核苷12，13及其双头无环C核苷。这些新化合物合成的目的是研究其抗菌活性。
• Process for producing hydrazinomonosaccharide derivatives and use thereof
  申请人：——

  公开号：US20040006221A1

  公开（公告）日：2004-01-08

  A process for producing hydrazinomonosaccharide derivatives and use of hydrazines in determining the structures of aldose and ketose monosaccharides located at the reducing ends of saccharides.

  一种生产肼基单糖衍生物的方法和使用肼类物质确定还原末端的醛糖和酮糖单糖的结构的方法。
• Synthesis of C-nucleoside precursors: alternative routes to 3-(polyhydroxyalkyl)-1,2,4-triazolo[3,4-a]phthalazines.
  作者：Mohammed A.E. Shaban、Mamdouh A.M. Taha

  DOI：10.1016/0008-6215(90)80034-z

  日期：1990.8

  Synthese de 3-[per-O-acetyl-L-galacto-(ou D-gluco-) pentitolyl]-6-phenyl-(ou 6-benzyl) 1,2,4-Triazolo [3,4-a] phtalazine et de 3-[per-O-acetyl-D-glycero-D-gulohexitolyl] 1,2,4-Triazolo [3,4-a] phtalazine a partir de la reaction d'1-hydrazino (ou 1-chloro) phtalazine (pouvant etre benzyle ou phenyle) avec soit les chlorures, hydrazides ou lactones d'acides aldoniques

  合成3- [全-O-乙酰基-L-半乳糖-（ou D-葡萄糖-）戊糖基] -6-苯基-（ou 6-苄基）1,2,4-三唑并[3,4-a]酞嗪等[3- [全-O-乙酰基-D-甘油-D-氨基己糖醇基] 1,2,4-三唑并[3,4-a]邻苯二甲'嗪反应'd'1-肼基（ou 1-chloro）邻苯二甲酰氯（pouvant etre苄基或苯基）乙酰氯，酰肼或内酯d'acides aldoniques
• [EN] NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER<br/>[FR] NOUVEAUX COMPOSES POSSEDANT UNE ACTIVITE INHIBITRICE DIRIGEE CONTRE LE TRANSPORTEUR DEPENDANT DU SODIUM
  申请人：TANABE SEIYAKU CO

  公开号：WO2005012326A1

  公开（公告）日：2005-02-10

  A compound of the formula (I) wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is -(CH2)n- (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  化合物的式子（I）其中环A和环B为：（1）环A是可选取代的不饱和单环杂环，环B是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A是可选取代的苯环，环B是可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或（3）环A是可选取代的不饱和融合杂双环，环B独立地是可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是碳原子或氮原子；Y是-(CH2)n-（n为1或2）；其药物可接受的盐或前药。
• Pharmaceutically active oligosaccharide conjugates
  申请人：Orlando Michele

  公开号：US20060100163A1

  公开（公告）日：2006-05-11

  The present invention relates to pharmaceutically active oligosaccharide conjugates having the formula: (X—Y m ) n —S, wherein component X is a pharmaceutically active compound, Y is a bifunctional linker, and S is an oligosaccharide consisting of 1 to 20 saccharide units, n is equal or less than the number of the saccharide units in the oligosaccharide S, and m is, independent of n, 0 or 1. In addition, the present invention is directed to a process of preparing compounds of the present invention, comprising the step of coupling compounents X and S directly or indirectly by means of a bifunctional linnker group. Furthermore, the present invention relates ot the use of said pharmaceutically active oligosaccharide conjugates as a medicament as well as to pharmaceutical compositions, freeze-dried pharmaceutical compositions, and a kit, all of which comprise at least one of said pharmaceutically active oligosaccharide conjugates.

  本发明涉及具有以下公式的药物活性寡糖共轭物：(X—Ym)n—S，其中成分X是药物活性化合物，Y是双功能连接剂，S是由1到20个糖基单元组成的寡糖，n小于等于寡糖S中糖基单元的数量，m是0或1，与n无关。此外，本发明涉及制备本发明化合物的过程，包括通过双功能连接剂直接或间接耦合化合物X和S的步骤。此外，本发明涉及将所述药物活性寡糖共轭物用作药物，以及包含至少一个所述药物活性寡糖共轭物的制药组合物、冻干制药组合物和试剂盒。